Mitral Valve Prolapse MVP

 

Mitral valve prolapse is a structural abnormality of the mitral valve that arises when part of its supporting apparatus—such as the leaflets, chordae tendineae, or papillary muscles—undergoes changes leading to altered valve function. These changes, often due to increased leaflet and chordal flexibility, elongation, or redundancy, cause one or both valve leaflets to bulge backward into the left atrium during systole. The condition is most frequently linked to myxomatous degeneration of the leaflets and chordae. The severity of associated mitral regurgitation depends on how much the prolapse interferes with proper leaflet coaptation. While mitral valve prolapse can occur without an identifiable cause, it is also seen in several inherited disorders, typically autosomal dominant or X-linked, such as Marfan syndrome, Ehlers-Danlos syndrome, adult polycystic kidney disease, osteogenesis imperfecta, pseudoxanthoma elasticum, systemic lupus erythematosus, polyarteritis nodosa, and muscular dystrophies. In addition, it is more frequently observed in patients with Graves’ disease, hypomastia, von Willebrand disease, sickle cell anemia, and rheumatic heart disease.

Watch Example Here>>

Detailed Discussion:

Mitral valve prolapse is a common structural abnormality of the mitral valve apparatus in which one or both mitral leaflets bulge (prolapse) back into the left atrium during ventricular systole. The condition spans a spectrum from incidental, clinically silent leaflet billowing to complex, myxomatous disease with bileaflet redundancy, chordal elongation or rupture, significant mitral regurgitation (MR), heart failure, arrhythmia, and—rarely—sudden cardiac death. Historically called floppy mitral valve syndrome or systolic click–murmur syndrome, modern imaging has clarified which leaflet morphologies are physiologic and which represent true pathologic prolapse; the contemporary working definition used in echocardiography is systolic displacement of leaflet tissue beyond the mitral annular plane into the left atrium by a measurable degree rather than vague “billowing.” This shift in definition reduced overdiagnosis and helped clinicians separate benign anatomic variants from disease that requires surveillance or intervention. 

Pathology underlying mitral valve prolapse most commonly involves myxomatous degeneration of the valve connective tissue. In myxomatous disease there is accumulation of proteoglycan in the spongiosa and fragmentation of collagen and elastic fibers in the fibrosa; the leaflets become thickened, redundant, and hyperextensible. Two commonly described clinicopathologic phenotypes are Barlow disease (marked bileaflet thickening and excess tissue, usually younger patients) and fibroelastic deficiency (thinner leaflets, focal chordal rupture, typically older patients with acute flail and severe regurgitation). Papillary muscles and chordae may be involved; chordal elongation or rupture produces flail segments and often sudden severe MR. There is a genetic component in many families, with autosomal dominant inheritance reported in some pedigrees and multiple implicated loci and genes related to extracellular matrix and structural proteins; however, the genetic architecture is heterogeneous and incompletely characterized. 

Clinically, many people with mitral valve prolapse are asymptomatic and discovered incidentally by auscultation (a mid-systolic click and/or late systolic murmur) or on echocardiography. Symptoms, when present, range from palpitations, atypical chest pain and exertional dyspnea to symptomatic MR with orthopnea and fatigue. Palpitations and arrhythmias are common complaints and are frequently benign premature ventricular or atrial complexes; in a small subgroup there is an association with malignant ventricular arrhythmias and sudden cardiac death (SCD). Risk markers that have been associated with a higher arrhythmic risk include bileaflet prolapse, marked leaflet redundancy, mitral annular disjunction (a separation between the atrial wall–mitral annulus junction and the ventricular myocardium), frequent complex ventricular ectopy, inferolateral T-wave changes on the ECG, and left ventricular or papillary muscle fibrosis seen on cardiac MRI. Overall, the absolute risk of SCD in MVP is low (conventionally quoted as <1% but varies by cohort and by how “arrhythmic MVP” is defined), yet attention to risk stratification is important because targeted interventions (medical therapy, catheter ablation, or surgical repair in select cases) can reduce arrhythmic burden and address triggers. 

Echocardiography is the diagnostic cornerstone for MVP and the primary tool for phenotyping and severity assessment. Transthoracic echo (TTE) in the parasternal long-axis view has been the classic location for diagnosis; criteria commonly used in modern practice define prolapse as systolic displacement of one or both mitral leaflets >2 mm beyond the mitral annular plane into the left atrium (measured in parasternal long axis or apical views), whereas billowing without true leaflet displacement or physiologic systolic bowing is not called pathologic MVP. A flail leaflet is one whose tip points into the left atrium and usually denotes chordal rupture; flail is often associated with severe MR. Two-dimensional imaging allows localization to specific scallops or segments (for example, P2 segment of the posterior leaflet) and helps plan repair; three-dimensional echocardiography improves visualization of scallop morphology, commissures, and the shape of the annulus and can be invaluable for surgical or percutaneous procedural planning. Color Doppler demonstrates MR jets (which may be eccentric), and Doppler methods are used to quantify regurgitation severity: vena contracta width, proximal isovelocity surface area (PISA) to estimate effective regurgitant orifice area (EROA), regurgitant volume, and assessment of pulmonary vein flow (systolic flow reversal in the pulmonary veins indicates severe MR). Additional helpful echo findings include left atrial enlargement, left ventricular dilation or dysfunction (which are consequences of chronic severe MR), and eccentric hypertrophy if volume overload is long-standing. Transesophageal echocardiography (TEE) provides superior resolution for detailed leaflet and subvalvular anatomy and is standard for intraoperative planning; cardiac magnetic resonance (CMR) is increasingly used when echo windows are limited or when precise quantification of regurgitant volume or myocardial fibrosis is needed. Contemporary guideline documents and echocardiography societies emphasize standardized image acquisition, strict measurement criteria, and integrated assessment rather than reliance on a single metric. 

Quantifying mitral regurgitation and its hemodynamic impact is essential because management hinges not just on the presence of prolapse but on MR severity and its physiological consequences. Mild MR often requires only periodic surveillance. Moderate or severe MR requires more active evaluation: assessment of symptoms, exercise capacity, left ventricular ejection fraction (LVEF), left ventricular end-systolic dimension (LVESD), left atrial size, pulmonary pressures, and the presence of atrial fibrillation. The international ACC/AHA valve guidelines recommend intervention for severe primary MR when symptoms attributable to MR are present or when there is evidence of LV dysfunction or significant chamber dilation (for primary MR, surgery is advised in symptomatic severe MR; in asymptomatic severe MR, surgery is recommended if LVEF is ≤60% or LVESD ≥40 mm, or if pulmonary hypertension or new atrial fibrillation develop). When repair is feasible, mitral valve repair is preferred over replacement because of better preservation of ventricular function and long-term outcomes; timing and choice of operation require a multidisciplinary heart-team discussion. These surgical thresholds are well established in guideline literature and form the backbone of decision-making in clinical practice. 

Management of MVP without significant MR is conservative: clinical reassurance for asymptomatic patients, routine follow-up with periodic auscultation and echocardiography to detect progression, treatment of arrhythmic symptoms with beta-blockers or antiarrhythmic strategies where indicated, and management of comorbidities. For patients with atrial fibrillation and significant MR, anticoagulation follows standard AF stroke-prevention rules. Infective endocarditis prophylaxis is not routinely recommended for most patients with MVP; guidelines reserve prophylaxis for a small subset of high-risk patients (for example, prosthetic valve recipients, prior endocarditis) rather than everyone with MVP. When MR is severe and meets guideline criteria, referral to a valve center experienced in mitral valve repair is recommended because durable repair yields superior outcomes. Percutaneous edge-to-edge therapies (for example, transcatheter clip repair) have become an important option in selected patients—particularly those at high surgical risk or with contraindications to surgery—and growing trial data support their benefit for symptomatic patients with severe MR in specified contexts; the role and patient selection for transcatheter approaches continue to evolve as trial evidence accumulates. Medical therapy aimed at heart-failure symptoms (diuretics, vasodilators where appropriate) may be used as temporizing measures or for patients who are not surgical candidates. 

Arrhythmia management in MVP requires a thoughtful, individualized approach. For benign symptomatic ectopy, reassurance, lifestyle measures (caffeine reduction, correction of electrolytes), and beta-blockers often suffice. For patients with frequent complex ventricular arrhythmias, syncope, or other high-risk features (bileaflet disease, mitral annular disjunction, myocardial fibrosis on CMR, non-sustained or sustained ventricular tachycardia), evaluation with ambulatory monitoring, exercise testing, and cardiac MRI is common; electrophysiology consultation may be needed. Catheter ablation can be effective when a clear arrhythmic focus is identified, and targeted ablation of papillary muscle or ventricular outflow tract sites has been described. There is emerging evidence that surgical repair—particularly when annuloplasty reduces the mechanical stressors that appear to trigger ventricular ectopy—can reduce arrhythmic burden in some patients with arrhythmic MVP, although a residual arrhythmic risk may persist and the decision to operate primarily for arrhythmia is nuanced. For patients with life-threatening ventricular arrhythmias or resuscitated cardiac arrest, implantable cardioverter-defibrillator (ICD) therapy follows established secondary-prevention indications; primary prevention ICD decisions in MVP are individualized and may be considered when multiple high-risk features coexist. The arrhythmogenic MVP phenotype is an active area of research, with evolving recommendations about who should be considered for advanced imaging, ablation, or surgery. 

Echocardiographic patterns that carry prognostic significance include the extent and location of leaflet prolapse (bileaflet disease tends to carry a different risk profile than single-segment prolapse), presence of flail segments, degree and direction of MR jet (central versus eccentric), progressive left ventricular dilation or dysfunction, and indirect markers such as pulmonary hypertension or left atrial enlargement. Advanced imaging with three-dimensional echo improves anatomic mapping for repair and may better predict the complexity of surgical reconstruction required, while CMR adds value by quantifying regurgitant volume when echo is inconclusive and by detecting myocardial fibrosis with late gadolinium enhancement—fibrosis that correlates with arrhythmic risk in multiple studies. Doppler-based quantification remains essential: guidance documents describe thresholds for MR severity using vena contracta width, EROA (with caveats about geometric assumptions), regurgitant volume, and the pull-together of multiple parameters to avoid misclassification. Accurate quantification matters because both undertreatment (delaying necessary repair) and overtreatment (unnecessary surgery) carry risks. 

From a population and prognosis standpoint, MVP prevalence estimates vary by the diagnostic criteria used and by the population studied, but conservative modern estimates place clinically relevant MVP in the low single-digit percentages of the general population (commonly cited ranges around 2–6% historically, though more restricted echo criteria yield lower current prevalence figures). Most patients with MVP have a normal life expectancy and do not require intervention; a minority develop progressive MR that requires repair, and a smaller subgroup has significant arrhythmic risk or other complications (infective endocarditis, stroke related to embolism in the setting of severe MR or atrial fibrillation). Because progression is variable and sometimes unpredictable, risk-based surveillance is the accepted strategy: regular clinical review, interval echocardiography based on MR severity and symptoms, and targeted advanced imaging where arrhythmic risk or quantification uncertainty exists. 

Research frontiers and unresolved questions remain active. The genetics of MVP are incompletely mapped and likely polygenic in many families; better molecular delineation might support future targeted therapies. The precise mechanisms by which valve-leaflet and annular mechanics interact with ventricular myocardium to create arrhythmic substrates are under study; this includes interest in mitral annular disjunction as a mechanical abnormality that may promote fibrosis in adjacent myocardium. Trials are refining the role of percutaneous therapies for primary MR due to MVP: while edge-to-edge repair is established in many contexts, defining which patients with degenerative MR (versus functional MR) will derive durable, superior outcomes from transcatheter techniques compared with surgical repair is ongoing. Long-term outcomes after repair versus replacement, optimal timing of intervention to preserve ventricular function, and strategies to prevent progression in at-risk but asymptomatic patients remain important clinical research questions. Registries and prospective studies that combine echo, CMR, ECG phenotyping, and genetic data are improving risk prediction for arrhythmic events and adverse remodeling. 

Practical clinical pearls that emerge from current evidence: use strict, reproducible echo criteria to avoid overcalling MVP; quantify MR integratively using multiple Doppler measures and consider CMR when echo is equivocal; refer patients with severe MR or complex anatomy to a multidisciplinary valve center where experienced surgeons or interventionalists can discuss repair options; screen for arrhythmic risk features (ECG abnormalities, frequent complex ventricular ectopy, symptoms of syncope or presyncope) and use ambulatory monitoring and CMR to further stratify risk when indicated; avoid routine endocarditis prophylaxis for isolated MVP in most patients but follow guideline criteria for the small high-risk subgroup; and remember that most patients have a benign course but that a thoughtful, individualized plan prevents under- or overtreatment. 

In summary, mitral valve prolapse is a heterogeneous clinical entity ranging from benign leaflet redundancy to complex myxomatous disease with severe mitral regurgitation and arrhythmic risk. Diagnosis and management rely on precise echocardiographic characterization, integrated hemodynamic quantification, recognition of arrhythmic risk markers (including advanced imaging with CMR when appropriate), and guideline-directed timing of intervention to preserve left ventricular function and alleviate symptoms. Recent advances in imaging, an evolving understanding of arrhythmogenic mechanisms, and the emergence of percutaneous repair options have expanded therapeutic choices but also increased the complexity of individualized decision making; shared evaluation in dedicated valve programs is often the best path to optimal outcomes. 

 #MitralValveProlapse #MVP #MyxomatousDegeneration #MitralRegurgitation #Echocardiography #CardiacMRI #MitralRepair #ValveDisease #ArrhythmicMVP #MitralAnnularDisjunction #Cardiology #HeartValve #ValveSurgery #TranscatheterMitralRepair

 #VentricularArrhythmia